Nadia Vie-Vezzio
Montpellier, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TopBP1 biomolecular condensates as a new therapeutic target in advanced-stage colorectal cancer.
Journal: eLife
Published: October 21, 2025
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.
Journal: Journal for immunotherapy of cancer
Published: March 01, 2025
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry.
Journal: International journal of molecular sciences
Published: May 02, 2022
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.
Journal: Cancer research
Published: September 11, 2018
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Journal: Molecular cancer therapeutics
Published: August 21, 2013
Specific extracellular matrix remodeling signature of colon hepatic metastases.
Journal: PloS one
Published: June 04, 2013
MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
Journal: Autophagy
Published: June 01, 2012
Selection for intrabody solubility in mammalian cells using GFP fusions.
Journal: Protein engineering, design & selection : PEDS
Published: October 15, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026